Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
about
Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection.Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review.Emerging drugs for hepatitis B.New aspects on the natural history of chronic hepatitis B infection: implication for therapy.Management of chronic hepatitis B in patients from special populationsAdvances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.Complications in treating chronic hepatitis B in patients with HIV.Review of tenofovir-emtricitabine.Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B.Effects of immunosuppressive drugs on HIV infection: implications for solid-organ transplantation.Future prospectives for the management of chronic hepatitis B.Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.Tenofovir for the treatment of hepatitis B virus.Management of HIV and hepatitis virus coinfection.Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase.Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.Treatment outcomes in a cohort of patients with chronic hepatitis B and human immunodeficiency virus co-infection in Mumbai, India.Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results.Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses.Role of tenofovir in the treatment of chronic HBV infection
P2860
Q33211869-2AEB89A0-08B5-4B2B-9B0D-7F1D94F0DC82Q33883722-2A95596C-628A-4A24-94EA-15EE50DD0A82Q34551836-1E8A547B-5E76-4CC3-843B-209F2B766DBCQ34712961-C1261DF1-304B-4143-9CAF-457B45FDA8D4Q35359369-0F65BAB5-297A-43B1-830B-F10CE1C46228Q35628953-D6179D3C-DBAB-450B-A405-BD893B8632A8Q35664183-50136AB8-797F-4042-A103-1769351A1E99Q35906015-2F817654-1454-4128-BBD8-41E9B933E8D9Q36135493-F710D8D5-9FFA-41EE-8D97-67BA18FD0A03Q36327100-24E5E3A5-531B-4DFB-918D-71393DFD2C0FQ36663686-601AA824-E8E4-455D-98F5-F8CDAD04D93DQ36756364-EF1EF3B1-BFBA-4A66-9F16-5772E567F5F8Q36787476-FE399F2D-11E3-483B-85B4-4EDF4588771FQ36841719-5CDFB4D4-B7EF-40C2-938E-98D904D7B12FQ36932959-C4649D47-9A34-4214-B5AA-080698B5C30DQ37149701-19999C78-BF57-41DF-8195-0E5A0ED11A2EQ37605886-0CA7F0B2-5C14-4EED-BEEB-72859B4F833AQ37772508-F23F2E82-9E64-454D-9711-A0D9EBD3F361Q38071400-0FC577DD-E397-415E-84FE-F53F693F1942Q41503130-FF28C0E1-6E07-4249-A7A2-6B464B5B1DACQ41604155-F0B3415F-A469-42E4-983E-CBCE50B82BCBQ42270170-0CD0BD7E-B6CC-414A-A5E1-68C8495FAE50Q43226767-96BBED1F-B2D4-49B8-B9AE-916C9489AD7CQ45441520-E0010C8C-0B46-4D7F-9B24-EED08D9C1608Q45450320-7ADBA2AE-E199-432C-9A3D-FAC65AC67C2AQ46044243-C9791C9B-5D6C-4521-8478-D8403355F9DBQ54256710-850AE515-0A60-4C43-8F84-7987D9BB46B3Q58098975-82C61663-2343-4A72-A9A1-67D74CCD9B4D
P2860
Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Tenofovir disoproxil fumarate ...... e-resistant hepatitis B virus.
@en
Tenofovir disoproxil fumarate ...... e-resistant hepatitis B virus.
@nl
type
label
Tenofovir disoproxil fumarate ...... e-resistant hepatitis B virus.
@en
Tenofovir disoproxil fumarate ...... e-resistant hepatitis B virus.
@nl
prefLabel
Tenofovir disoproxil fumarate ...... e-resistant hepatitis B virus.
@en
Tenofovir disoproxil fumarate ...... e-resistant hepatitis B virus.
@nl
P2093
P1476
Tenofovir disoproxil fumarate ...... e-resistant hepatitis B virus.
@en
P2093
Roland Tubiana
Vincent Thibault
Yves Benhamou
P304
P356
10.1056/NEJM200301093480218
P407
P577
2003-01-01T00:00:00Z